Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

Following 13 weeks of treatment with once-nightly sodium oxybate, some patients in the 7.5 g and 9.0 g groups showed complete resolution of cataplexy attacks.

Once-Nightly Sodium Oxybate Shows Significant Impact on Cataplexy Attacks, Post-Hoc Analysis Shows

PUMAS significantly alleviated depression relative to controls whereas cognitive behavioral therapy-insomnia did not differ from either group.

PUMAS Intervention Results in Greater Insomnia Remission Rates, Reduced Depression in Prenatal Insomnia Than CBT-I

Videos

The professor of neurology at Washington University School of Medicine discussed progressive multiple sclerosis and the need for targeted therapies to address the progression and associated challenges. [WATCH TIME: 5 minutes] 

New Insights on Discovering Targeted Therapies for Progressive MS: Anne H. Cross, MD

Among patients with post-acute sequelae from COVID-19 infection, self-reported cognitive symptoms were correlated with severity of fatigue, anxiety, and depression, but not subjective sleep disturbance.

Post-COVID Abnormal Sleep is Common, With Potential Impacts on Cognition

Professor of Neurology; Section Head, Neuroimmunology/MS, Washington University School of Medicine

Associate professor of neurological sciences and chief of the Multiple Sclerosis Division at the University of Vermont in Burlington.

At CMSC 2023, the associate professor of neurological sciences at the University of Vermont in Burlington talked about data surrounding multiple sclerosis diagnosis and misdiagnosis, suggesting the need for the development of diagnostic biomarkers. [WATCH TIME: 5 minutes] 

Challenges and Advancements in Biomarkers for Accurate Diagnosis in MS: Andrew Solomon, MD

At CMSC 2023, the professor of neurology at Barts and The London School of Medicine and Dentistry discussed the emerging paradigm shift in understanding multiple sclerosis (MS) as a smoldering disease and the potential role of Epstein Barr Virus in causing MS. [WATCH TIME: 6 minutes]

Rethinking MS as a Smoldering Disease and the Role of the Epstein Barr Virus: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath

Speech-Language Pathologist, Orlando Health.

At CMSC 2023, the neuromuscular and movement disorders speech-language pathologist at Orlando Health discussed the importance of early intervention in speech and communication therapy, as well as the challenges faced in getting patients to seek therapy at the time of diagnosis. [WATCH TIME: 5 minutes] 

Overcoming Challenges and Early Intervention for Speech Therapy in MS: Rachel Haines, MA, CCC-SLP, MSCS, CBIS

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Mini Quiz: Beers Criteria

NeurologyLive® Brain Games: June 4, 2023

Episode 88: 2023 AAN Annual Meeting Highlights

NeurologyLive® Friday 5 — June 2, 2023

Special Episode: Lecanemab Approved for Alzheimer Disease

This Week on NeurologyLive® — May 29, 2023

NeurologyLive® Brain Games: May 28, 2023

NeurologyLive® Brain Games: June 4, 2023

Episode 88: 2023 AAN Annual Meeting Highlights

NeurologyLive® Friday 5 — June 2, 2023

Special Episode: Lecanemab Approved for Alzheimer Disease

This Week on NeurologyLive® — May 29, 2023

NeurologyLive® Brain Games: May 28, 2023

NeurologyLive® Brain Games: June 4, 2023

Episode 88: 2023 AAN Annual Meeting Highlights

NeurologyLive® Friday 5 — June 2, 2023

Special Episode: Lecanemab Approved for Alzheimer Disease

This Week on NeurologyLive® — May 29, 2023

NeurologyLive® Brain Games: May 28, 2023